Clinical Trials Logo

Filter by:
NCT ID: NCT00149201 Completed - Gastric Cancer Clinical Trials

A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis

Start date: November 2002
Phase: Phase 3
Study type: Interventional

To develop effective chemotherapy regimen against gastric cancer with peritoneal metastasis

NCT ID: NCT00147316 Completed - Cerebral Infarction Clinical Trials

Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke

Start date: April 2002
Phase: Phase 3
Study type: Interventional

Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved dosage of 0.9mg/kg, aiming to assess the efficacy and safety of alteplase for the Japanese.

NCT ID: NCT00147147 Completed - Gastric Neoplasm Clinical Trials

Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)

Start date: January 1993
Phase: Phase 3
Study type: Interventional

To evaluate the survival benefit of adjuvant chemotherapy after curative resection with D2 or greater lymph node dissection in T3-4 gastric cancer patients.

NCT ID: NCT00147134 Completed - Colorectal Cancer Clinical Trials

A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate oncological outcome of patients for T3 and T4 colorectal cancer undergoing laparoscopic versus open surgery.

NCT ID: NCT00147121 Completed - Lymphoma, B-Cell Clinical Trials

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Start date: September 2002
Phase: Phase 2/Phase 3
Study type: Interventional

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

NCT ID: NCT00145002 Completed - Lymphoma Clinical Trials

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Start date: August 1998
Phase: Phase 3
Study type: Interventional

To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.

NCT ID: NCT00144989 Completed - Clinical trials for Small-Cell-Lung Cancer

A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

Start date: September 2002
Phase: Phase 3
Study type: Interventional

To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

NCT ID: NCT00144339 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.

NCT ID: NCT00144222 Completed - Hypertension Clinical Trials

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy.

NCT ID: NCT00143611 Completed - Sepsis Clinical Trials

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.